Advertisement

Journal of Neurology

, Volume 254, Issue 11, pp 1547–1554 | Cite as

Outcome of beta-interferon treatment in relapsing-remitting multiple sclerosis: a Bayesian analysis

  • K. O'Rourke
  • C. Walsh
  • M. Hutchinson
ORIGINAL COMMUNICATION

Abstract

Observational studies of the effect of beta-interferon (IFNβ) on accumulation of fixed disability in relapsing remitting multiple sclerosis (RRMS) in clinical practice have been difficult to interpret due to bias. The aim of this study of 175 RRMS patients was to use Bayesian analysis to establish whether IFNβ attenuates disability relative to a cohort of matched historical control subjects from the Sylvia Lawry Centre for MS Research. A sensitivity analysis was based on a range of prior probability distributions for IFNβ efficacy derived from a published meta-analysis of randomised controlled trials (RCTs) of IFNβ, and the data were interpreted both unmodified and using variance inflation and point estimate bias correction; the corrected data interpreted in the light of the most likely prior probability distribution yielded a 95 % posterior credible interval for the odds ratio of accumulation of fixed disability after two years of IFNβ therapy of 0.52, 0.94. It is concluded that two years of IFNβ therapy for RRMS reduces accumulation of fixed disability in clinical practice.

Key words

multiple sclerosis beta-interferon Bayesian analysis historical control fixed disability odds ratio 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    IFNβ Multiple Sclerosis Study Group, the University of British Columbia MS/MRI analysis group (1995) Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomised controlled trial.Neurology 45:1277–1285Google Scholar
  2. 2.
    Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, et al. (1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 39:285–294CrossRefPubMedGoogle Scholar
  3. 3.
    PRISMS study group (1998) Randomized double-blind placebo-controlled study of interferon beta-1a in relapsing remitting multiple sclerosis. Lancet 352:1498–1504CrossRefGoogle Scholar
  4. 4.
    Rabeneck L, Viscoli CM, Horwitz RI (1992) Problems in the conduct and analysis of randomised clinical trials: are we getting the right answers to the wrong questions? Arch Intern Med 152:507–512CrossRefPubMedGoogle Scholar
  5. 5.
    Vandenbroucke JP (2004) When are observational studies as credible as randomised trials? Lancet 363:1728–1731CrossRefPubMedGoogle Scholar
  6. 6.
    Ashby D, Hutton JL, McGee MA (1993) Simple Bayesian analyses for case-control studies in cancer epidemiology. Statistician 42:385–397CrossRefGoogle Scholar
  7. 7.
    Bergamaschi R, Berzuini C, Romani A, Cosi V (2001) Predicting secondary progression in relapsing-remitting multiple sclerosis: a Bayesian analysis. J Neurol Sci 189:13–21CrossRefPubMedGoogle Scholar
  8. 8.
    Parmar MKB, Ungerleider RS, Simon R (1996) Assessing whether or not to perform a randomised clinical trial. J Natl Cancer Inst 88:1645–1651CrossRefPubMedGoogle Scholar
  9. 9.
    Poser CM, Paty DW, Scheinberg LC, McDonald WI, Davis FA, Ebers GC, et al. (1983) New diagnostic criteria for multiple sclerosis: Guidelines for research protocols. Ann Neurol 13:227–231CrossRefPubMedGoogle Scholar
  10. 10.
    Kurtzke JF (1983) Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:1444–1452PubMedGoogle Scholar
  11. 11.
    Rio J, Nos C, Tintore M, Borras C, Galan I, Comabella M, et al. (2002) Assessment of different treatment failure criteria in a cohort of relapsing-remitting multiple sclerosis patients treated with interferon beta: implications for clinical trials. Ann Neurol 52:400–406CrossRefPubMedGoogle Scholar
  12. 12.
    Fillipini G,Munari L, Incorvaia B, Ebers GC, Polman C, D’Amico R, et al. (2003) Interferons in relapsing remitting multiple sclerosis: a systematic review. Lancet 361:545–552CrossRefGoogle Scholar
  13. 13.
    Spiegelhalter DJ, Freedman LS, Parmar MKB (1994) Bayesian approaches to randomised trials. J Roy Stat Soc Series A 157:357–387Google Scholar
  14. 14.
    O'Rourke KET, Hutchinson M (2005) Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns. Mult Scler 11:46–50CrossRefPubMedGoogle Scholar
  15. 15.
    Carra A, Onaha P, Sinay V, Alverez F, Luetic G, Bettinelli R, et al. (2003) A retrospective, observational study comparing the four available immunomodulatory treatments for relapsing-remitting multiple sclerosis. Eur J Neurol 10:671–676CrossRefPubMedGoogle Scholar
  16. 16.
    Rio J, Tintore M, Nos C, Tellez N, Galan I, Montalban X (2005) Interferon beta in relapsing-remitting multiple sclerosis. An eight years experience in a specialist multiple sclerosis centre. J Neurol 252:795–800CrossRefPubMedGoogle Scholar
  17. 17.
    Arbizu T, Alverez-Cermeno JC, Decap G, Fernandez O, Uria DF, Garcia Merino A, et al. (2000) Interferon beta- 1b treatment in patients with relapsing-remitting multiple sclerosis under a standardized protocol in Spain, Acta Neurol Scand 102:209–217CrossRefPubMedGoogle Scholar
  18. 18.
    Trojano M, Liguori M, Paolicelli D, Bosco Zimatore G, De Robertis F, Avolio C, et al. (2003) Interferon beta in relapsing-remitting multiple sclerosis: an independent postmarketing study in southern Italy. Mult Scler 9:451–457CrossRefPubMedGoogle Scholar
  19. 19.
    Dubois BD,Keenan E, Porter BE, Kapoor R, Rudge P, Thompson AJ, et al. (2003) Interferon beta in multiple sclerosis: experience in a British specialist multiple sclerosis centre. J Neurol Neurosurg Psychiatry 74:946–949CrossRefPubMedGoogle Scholar
  20. 20.
    Milanese C, La Mantia L, Palumbo R, Martinelli V, Murialdo A, Zaffaroni M, et al. (2003) A post-marketing study on interferon β 1b and 1a treatment in relapsing-remitting multiple sclerosis: different response in drop-outs and treated patients. J Neurol Neurosurg Psychiatry 74:1689–1692CrossRefPubMedGoogle Scholar
  21. 21.
    Weinshenker BG, Bass B, Rice GP, Noseworthy J, Carriere W, Baskerville J, et al. (1989) The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course. Brain 112:1419–1428CrossRefPubMedGoogle Scholar
  22. 22.
    Marrie RA, Cutter G, Tyry T, Hadjimichael O, Campagnolo D, Vollmer T (2005) Changes in the ascertainment of multiple sclerosis.Neurology 65:1066–1070CrossRefPubMedGoogle Scholar
  23. 23.
    Thygesen P (1953) The course of multiple sclerosis. Copenhagen: Rosenkilde and BaggenGoogle Scholar
  24. 24.
    Liu C, Blumhardt LD (2000) Disability outcome measures in therapeutic trials of relapsing-remitting multiple sclerosis: Effects of heterogeneity of disease course in placebo cohorts. J Neurol Neurosurg Psychiatry 68:450–457CrossRefPubMedGoogle Scholar
  25. 25.
    Kremenchutzky M, Cottrell D, Rice G, Hader W, Baskerville J, Koopman W, et al. (1999) The natural history of multiple sclerosis: a geographically based study. 7. Progressive-relapsing and relapsing-progressive multiple sclerosis: a re-evaluation. Brain 122:1941–1950CrossRefPubMedGoogle Scholar
  26. 26.
    Wolpert RL, Mengersen KL (2004) Adjusted likelihoods for synthesizing empirical evidence from studies that differ in quality and design: effects of environmental tobacco smoke. Stat Sci 19:450–471CrossRefGoogle Scholar
  27. 27.
    Lilford RJ, Braunholtz D (1996) The statistical basis of public policy: a paradigm shift is overdue. BMJ 313:603–607PubMedGoogle Scholar
  28. 28.
    Schulz KF, Chalmers I, Grimes DA, Altman DG (1994) Assessing the quality of randomisation from report of controlled trials published in obstetrics and gynaecology journals. JAMA 272:125–128CrossRefPubMedGoogle Scholar
  29. 29.
    Sacks H, Chalmers T, Smith H (1982) Randomised versus historical controls for clinical trials. Am J Med 72:233–240CrossRefPubMedGoogle Scholar

Copyright information

© Steinkopff-Verlag 2007

Authors and Affiliations

  1. 1.Dept. of StatisticsTrinity CollegeDublinIreland
  2. 2.Dept. of NeurologySt. Vincent’s University HospitalDublin 4Ireland

Personalised recommendations